Our findings provide evidence for a potential cardiovascular protective effect of allopurinol in patients with gout and diabetes, a group of patients at high risk for cardiovascular events, the researchers concluded.

A large proportion of patients with gout have uncontrolled disease, according to recent research published in The Journal of Rheumatology. These patients have significantly worse functioning, quality of life, and work productivity.
Gout is a common and painful condition that is manageable, and treatment guidelines are available. Despite this, several studies suggest management is suboptimal.
By Rosemary Frei, MSc Montreal, Quebec—Dual-energy computed tomography (DECT) has value in gout diagnosis and management, according to a presentation at the Canadian Association of Radiologists’ 2013 annual meeting.
Although gout is a common disease that may have serious consequences, numerous studies show that gout is often misdiagnosed and that its management is suboptimal. New evidence-based guidelines for the management of gout from the European League Against Rheumatism (EULAR), published on July 25, 2016, have been developed in the hopes of remedying these issues.
Although the efficacy of febuxostat has been shown in el­derly patients, its efficacy is unclear in elderly women with hyperuricemia.
Gout affects 1% to 2% of adults in Western countries and 2.5% of adults in the United Kingdom. Compared with the general population, patients with gout have increased cardiovascular morbidity and mortality, and researchers largely attribute this increased risk to urate levels.
By Neil Canavan For the first time in its 78-year history, the American College of Rheumatology (ACR) has issued guidelines for the management of gout in October, which were published in 2 parts (Khanna D, et al. Arthritis Care Res. 2012;64:1431-1461).
Charlotte, NC—How many rheumatologists can say they can cure gout? Not many can confidently say so, according to an informal poll taken during the 2014 North Carolina Rheumatology Association annual meeting.
By Barbara Schwedel Washington, DC—Gout affects ap­proximately 1% to 2% of the US population. The results of 2 recent studies involving patients with gout were presented at a poster session during the 2012 International Society for Pharma­coeconomics and Outcomes Research (ISPOR) annual meeting.
Page 1 of 3
Results 1 - 10 of 30
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology